Aksu, SalihSahin, FahriUz, BurakYavuz, Selim A.Atay, HilmiKelkitli, EnginTurgut, Mehmet2024-06-122024-06-1220121306-133Xhttps://doi.org/10.4999/uhod.12004https://hdl.handle.net/20.500.14551/19805We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.en10.4999/uhod.12004info:eu-repo/semantics/openAccessChronic Myeloid LeukemiaDasatinibTreatment DosageChronic Myelogenous LeukemiaTyrosine Kinase InhibitorNilotinib Formerly Amn107Chronic-PhaseBcr-AblImatinib ResistanceTherapyFailureNonadherenceIntoleranceArticle221814Q4WOS:000306389200002